Follow-up of offspring and mothers with gestational diabetes treated with metformin or glibenclamide: A randomized controlled trial.

A 9-year follow-up of a randomized controlled trial showed metformin to have better neonatal outcomes than glibenclamide. Treatment options for moderate gestational diabetes mellitus include metformin and glibenclamide. A randomized controlled trial[3] performed 9 years ago comparing the use of metformin and glibenclamide showed significantly better neonatal outcomes with the use of metformin. The present study followed up 78 (49%) of 159 women that were randomized, along with their offspring, to compare adiposity, anthropometric measurements, and prevalence of diabetes between the two treatment groups.